20.76

3.71% -0.80

After Hours: 20.76

Zenas Biopharma Inc (ZBIO)

Overview News Price History Discussions Forecast

Zenas Biopharma Inc stock is traded at $20.76, with a volume of 398.56K. It is down -3.71% in the last 24 hours and down -3.26% over the past month. Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them. The Company manages its operations on a consolidated basis as a single reportable segment focused on the research, development and commercialization of transformative immunology-based therapies.

Previous Close:

$21.56

Open:

$21.68

24h Volume:

398.56K

Relative Volume:

0.52

Market Cap:

$1.29B

Revenue:

$10.00M

Net Income/Loss:

$-377.74M

P/E Ratio:

-2.4587

EPS:

-8.4436

Net Cash Flow:

$-172.35M

1W Performance:

+15.27%

1M Performance:

-3.26%

6M Performance:

-32.00%

1Y Performance:

+84.70%

1-Day Range:

$20.27

$22.15

1-Week Range:

$17.39

$22.15

52-Week Range:

$8.51

$44.60

Zenas Biopharma Inc Stock (ZBIO) Company Profile

Name

Zenas Biopharma Inc

Sector

Healthcare (1106)

Industry

Biotechnology (615)

Phone

857-271-2954

Address

852 WINTER STREET, SUITE 250, WALTHAM

Employee

167

Twitter

Next Earnings Date

2026-05-21

Latest SEC Filings

ZBIO's Discussions on Twitter

Compare ZBIO vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ZBIO Zenas Biopharma Inc	20.76	1.34B	10.00M	-377.74M	-172.35M	-8.4436
VRTX Vertex Pharmaceuticals Inc	424.36	109.34B	12.32B	4.34B	3.19B	16.86
REGN Regeneron Pharmaceuticals Inc	702.27	74.35B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	794.70	50.44B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	301.11	39.78B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	297.49	33.02B	5.36B	287.73M	924.18M	2.5229

Zenas Biopharma Inc Stock (ZBIO) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-05-26	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Mar-20-25	Initiated	Wedbush	Outperform
Feb-04-25	Initiated	Wolfe Research	Outperform
Dec-16-24	Initiated	H.C. Wainwright	Buy
Nov-05-24	Initiated	Rodman & Renshaw	Buy
Oct-08-24	Initiated	Citigroup	Buy
Oct-08-24	Initiated	Guggenheim	Buy
Oct-08-24	Initiated	Jefferies	Buy
Oct-08-24	Initiated	Morgan Stanley	Overweight

View All

Zenas Biopharma Inc Stock (ZBIO) Latest News

04:15 AM

Zenas BioPharma (ZBIO) CEO and entities report 3,220,880 shares owned - Stock Titan

04:15 AM

08:47 AM

Zenas BioPharma rises as CEO continues insider purchases - MSN

08:47 AM

May 04, 2026

A Look At Zenas BioPharma (ZBIO) Valuation After Obexelimab Trial Success And US$300 Million Fundraising - Sahm

May 04, 2026

May 01, 2026

ZBIO Stock Price, Quote & Chart | ZENAS BIOPHARMA INC (NASDAQ:ZBIO) - ChartMill

May 01, 2026

Zenas BioPharma (ZBIO) Price Target Increased by 21.59% to 40.22 - MSN

May 01, 2026

Apr 30, 2026

Zenas: 'Strong Buy' On Obexelimab Enhancement And Expected SLE Data Q4 2026 (NASDAQ:ZBIO) - Seeking Alpha

Apr 30, 2026

Zenas BioPharma (NASDAQ:ZBIO) Shares Gap Up on Insider Buying Activity - MarketBeat

Apr 30, 2026

Zenas BioPharma rises on CEO insider purchase (ZBIO:NASDAQ) - Seeking Alpha

Apr 30, 2026

Apr 29, 2026

Zenas BioPharma CEO Makes Bold Move With Major Personal Stock Buy - TipRanks

Apr 29, 2026

Zenas BioPharma CEO Moulder buys $1.07m in ZBIO shares By Investing.com - Investing.com Canada

Apr 29, 2026

Leon Moulder Jr Purchases 25,000 Shares of Zenas BioPharma (NASDAQ:ZBIO) Stock - MarketBeat

Apr 29, 2026

Zenas BioPharma CEO Moulder buys $1.07m in ZBIO shares - Investing.com UK

Apr 29, 2026

Zenas BioPharma (ZBIO) CEO-linked entities purchase 60,000 shares in open market - Stock Titan

Apr 29, 2026

Apr 26, 2026

Zenas BioPharma announces concurrent public offerings of convertible senior notes and common stock - MSN

Apr 26, 2026

Apr 21, 2026

Here’s Why Zenas BioPharma (ZBIO) Traded Lower in Q1 - Insider Monkey

Apr 21, 2026

Zenas Biopharma, Daqo New Energy and other big stocks moving lower in Friday's pre-market session - MSN

Apr 21, 2026

Apr 20, 2026

Zenas BioPharma, Inc. (NASDAQ:ZBIO) Given Average Rating of "Hold" by Analysts - MarketBeat

Apr 20, 2026

Is Zenas BioPharma (ZBIO) stock priced efficiently (Weakens) 2026-04-20Community Pattern Alerts - Cổng thông tin điện tử tỉnh Lào Cai

Apr 20, 2026

Apr 17, 2026

Zenas Biopharma announces inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com

Apr 17, 2026

Zenas Biopharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView

Apr 17, 2026

Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Apr 17, 2026

Zenas BioPharma, Inc. Investigated by the Portnoy Law Firm - GlobeNewswire

Apr 17, 2026